Skip to main content

AKTEN

Generic: LIDOCAINE HYDROCHLORIDE ANHYDROUS

Verified·Apr 23, 2026
Manufacturer
Thea
NDC
82584-792
RxCUI
1009462
Route
OPHTHALMIC
ICD-10 indication
H57.10

Affordability Check

How much will you actually pay for AKTEN?

In 30 seconds, see every legitimate way to afford AKTEN — Medicare copay, manufacturer copay card, Patient Assistance Program, grants, or cash.

Check my options →

About AKTEN

What is this medication? Akten is a prescription local anesthetic that contains lidocaine hydrochloride in a gel form. It is specifically designed for ophthalmic use, meaning it is applied directly to the surface of the eye. Its primary function is to provide rapid and effective numbing of the ocular tissues to prevent pain or discomfort during medical procedures.

Healthcare professionals typically administer this medication before surgeries, such as cataract removal or LASIK, and during certain types of diagnostic examinations or injections. By blocking nerve signals in the eye, the gel ensures that the patient remains comfortable while the doctor performs the necessary work. The numbing effect is temporary and allows for minor surgical manipulations without the need for general anesthesia.

Copay & patient assistance

Detailed copay and financial assistance information is not publicly available for this medication at this time. Please consult your pharmacist or the manufacturer's official patient support program for more details.

External links go directly to the manufacturer's portal. RxCopays does not receive compensation for referrals.

Compare pricing elsewhere

RxCopays doesn't sell drugs or take referral fees. Here are the transparent-pricing directories we recommend checking alongside your insurance formulary.

We deep-link because transparency helps patients. None of these partners pay RxCopays.

Prescribing information

From the FDA-approved label for AKTEN. Official source: DailyMed (NLM) · Label effective Dec 8, 2025

Contraindications
4 CONTRAINDICATIONS None. None. ( 4 )
Use in pregnancy
8.1 Pregnancy Risk Summary There are no adequate and well-controlled studies with AKTEN in pregnant women to inform a drug-associated risk. In animal reproduction studies, subcutaneous administration of lidocaine to pregnant rats at doses >800-fold the human dose based on body surface area did not result in adverse developmental effects. The estimated background risk of major birth defects and miscarriage for the indicated population(s) is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

Label text is reproduced as-is from the FDA-approved label. We do not paraphrase, summarize, or omit. Content above is for informational purposes only and is not medical advice. Always consult your prescribing clinician or pharmacist before making decisions about your medication.

Conditions we've indexed resources for

Click a condition to see copay cards, grants, and PA rules specific to it. For the full list of FDA-approved indications, see Prescribing information above.

Prior authorization & coverage

PayerPAStep therapyCopay tier

Medicare Part D

Related drugs

How this page is sourced

  • Drug identity verified against openFDA NDC Directory.
  • Label text (when shown) originates from NLM DailyMed.
  • Copay and assistance URLs verified periodically; if you hit a broken link, tell us.